LETTER TO THE EDITOR

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

Matteo Allegretti¹, Alessandra Fabi²,³, Elena Giordani¹, Cristiana Ercolani⁴, Paolo Romania¹, Cecilia Nisticò³, Simona Gasparro³, Vittoria Barberi⁵, Maria Ciolina⁶, Edoardo Pescarmona⁴, Diana Giannarelli⁷, Gennaro Ciliberto⁸, Francesco Cognetti⁹ and Patrizio Giacomini¹

Keywords: HER2+ breast cancer, T-DM1, Liquid biopsy, Circulating tumor DNA, Pharmacological resistance

Main text
Breast carcinomas of the HER2-positive subtype (HER2 BC) are oncogene addicted, e.g. they rely on a single dominant cancer driver. Pathway hyperactivation is successfully counteracted by a variety of therapeutic agents (small molecules and antibodies) mostly in association with chemotherapy [1, 2]. Recently approved in the adjuvant setting [3], for many years T-DM1 has been standard of care (SoC) in advanced HER2 BC following Trastuzumab/Pertuzumab treatment, although lesser than expected objective responses were observed [4, 5]. Pharmacological resistance to T-DM1 has been associated with several direct or bypass alterations of the HER2 pathway (reviewed in [6]), but most of these were observed in preclinical models only [7–11]. Liquid biopsy (LB) provides instead a unique opportunity to non-invasively capture resistance traits in the clinical setting [12].

Patients and study design
The LiqBreasTrack cohort study was conducted at the Regina Elena National Cancer Institute from November 2016 to February 2021 to assess tumor molecular alterations occurring in blood under T-DM1 pressure, and recapitulate adaptive tumor evolution in archival tissues (Fig. S1). Eligibility and T-DM1 administration were as per SoC. Demographics and clinical pathological features are presented in Table 1. The study was approved by the competent Ethical Review Board (RS-857/16). Patients signed a written informed consent including the option of re-biopsy. Tumor tissues (n = 28) and blood drawings (n = 337) were tested by targeted NGS and dPCR (Supplementary Methods and Fig. S2a-b). Progression-free survival (PFS) was calculated between the first T-DM1 administration and progressive disease or last follow-up. Data elaboration was by descriptive statistics and Graph-PAD Prism v8.3 (GraphPad Software, CA, USA).

Results and discussion
Clinical response to T-DM1
Twenty patients were compliant with the study plan, 2 are still on treatment at the time of writing with no sign of progression, and 2 were lost to follow-up. Partial response (PR), stable disease (SD) and progressive disease (PD) were seen in 12 (60%), 5 (25%) and 3 (15%) evaluable patients, respectively. No complete response was observed.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Table 1 Demographics and clinical pathological features of LiqBreasTrack-enrolled patients

| Characteristics                                      | N (%)       |
|------------------------------------------------------|-------------|
| Age, years (range)                                   | 56.8 (39.4–83.5) |
| ECOG Performance Status ≤ 2                         | 22 (100)    |
| IHC molecular markers                                |             |
| Primary tumor tissues                                | 22          |
| ER+ and/or PgR+                                      | 15 (68.2)   |
| ER- and/or PgR-                                      | 7 (31.8)    |
| HER2 1+/SISH or FISH+                                | 3 (13.6)    |
| HER2 2+/SISH or FISH+                                | 2 (9.1)     |
| HER2 3+                                              | 17 (77.3)   |
| Metastatic tumor tissues                             | 9           |
| ER+ and/or PgR+                                      | 6 (66.7)    |
| ER- and/or PgR-                                      | 3 (33.3)    |
| HER2 1+/SISH or FISH+                                | 1 (11.1)    |
| HER2 2+/SISH or FISH+                                | 3 (33.3)    |
| HER2 3+                                              | 5 (55.6)    |
| Previous lines of therapy                            |             |
| 1                                                    | 14 (63.6)   |
| 2                                                    | 7 (31.8)    |
| 3                                                    | 1 (4.5)     |
| Pertuzumab as first line treatment                   |             |
| Yes                                                  | 9 (40.9)    |
| No                                                   | 13 (59.1)   |
| Dominant Metastatic sites                            |             |
| Liver                                                | 3 (13.6)    |
| Lung                                                 | 3 (13.6)    |
| Bone                                                 | 5 (22.7)    |
| Soft tissues                                         | 7 (31.9)    |
| Brain                                                | 4 (18.2)    |
| Number of metastatic sites per patient               |             |
| 1                                                    | 8 (36.6)    |
| 2                                                    | 9 (40.9)    |
| ≥ 3                                                  | 5 (22.7)    |

Previous therapy lines included: Lapatinib plus Capecitabine, Trastuzumab plus Vinorelbine, Trastuzumab plus Carboplatin
IHC Immunohistochemistry, ER Estrogen receptor, PgR Progesterone receptor, SISH/FISH Silver in situ hybridization/Fluorescent in situ hybridization

Progressive reversal of HER2 amplification in tissues and blood

Tissues and plasma from the LiqBreasTrack study were tested by a dPCR assay shown by others to quantitatively detect HER2 amplification [13, 14]. Due to normal DNA present in blood and in tissues with an abundant stromal component, absolute copy numbers are underestimated by the assay [14, 15]. Nevertheless, dPCR was accurate and quantitative also in our hands, as shown by its remarkable concordance with NGS (Fig. S2c-d). Testing all samples under identical conditions clearly documented progressive HER2 counter-selection. HER2 amplification was detected in 7/11 (64%) primary tumors but only 5/12 (42%) metastatic lesions collected during previous anti-HER2 treatments, and in 7/20 (35%) blood drawings collected before T-DM1 treatment, but only 2/20 (10%) overall blood drawings at progression (Fig. 1a-b). HER2 counterselection in blood was confirmed in 3/4 matched (from the same patient) tumor re-biopsies at progression, the only exception being a HER2-positive brain metastasis developing against a HER2-neutral blood background (pt#5; Fig. S3). Interestingly, median PFS did not significantly differ depending on the HER2 blood status (amplified vs neutral) at baseline (Fig. 1c). Perhaps, like Trastuzumab Deruxtecan [16] T-DM1 remains active on tumors with attenuated HER2 signalling, e.g. a HER2-neutral, but druggable, status spans a much larger patient cohort and a much wider time window than appreciated so far.

Remodeling in oncogenic dependencies

Breast cancer alterations other than HER2 amplification were identified and sorted out in 3 steps. First, orthogonal testing with targeted NGS and alteration-specific dPCR assays of 28 tumor tissues (patient n = 14) and 337 plasma samples (patient n = 20) concordantly detected 150 and 27 mutational hits, respectively. Second, dPCR testing detected 3 of the above hits in genomic DNAs from the peripheral blood mononuclear cells (PBMCs) of 2 distinct patients, demonstrating the occasional origin of some alterations from clonal haematopoiiesis (Fig. S4). Filtering these 3 hits out left 147 and 24 hits in tissues and plasma respectively, all deemed to represent genuine breast cancer alterations. Third, counting each alteration once (several hits recurred in different samples and patients) yielded a total of 136 and 15 unique tumor variants. A synopsis of patients, clinical-biological features, and a list of genes with detectable alterations is displayed in Fig. S5a-b. Interestingly, 14 of the 15 unique tumor variants seen in plasma were detected in a subset of 12 patients with at least one available, matched tissue sample, making it possible to calculate that only 7 variants were shared between tissue and blood in this representative subset, whereas the remaining 7 were observed in blood only (Fig. S5c). Altogether, HER2 neutralization and the appearance of new variants in blood suggest an extensive remodeling in oncogenic dependencies that would have been missed by tissue-only bulk sequencing.

LB dynamics hint at several distinct clonal selection mechanisms

Since blood was drawn every 21 days, on the occasion of each T-DM1 administration, detailed clonal
trajectories could be assessed. Alterations undergoing at least two consecutive >1.5-fold increases in their VAFs were assumed to mark clonal expansion. Depending on whether immediately evident or delayed (e.g. since the first blood drawing or afterwards), clonal expansions were consistent with primary and adaptive pharmacological resistance, respectively (Fig. S6a-b). In contrast, clonal contractions (defined as a reduction by >50%) were invariably steep, e.g. they occurred abruptly, typically after a single T-DM1 administration (Fig. S6c). For instance, HER2 and some PIK3CA mutations known to confer resistance to previous anti-HER2 treatments [17, 18] were irreversibly wiped off within weeks despite they had been selected during years of previous therapies, as documented in archival tumor tissues (Fig. S5a). Overall, swift clonal suppression provides a rationale for innovative pulse dosing/de-escalation schedules. In selected patients, these may elicit response with minimal treatment-associated toxicity.

**LB anticipates progression at extracranial locations**

The LiqBreasTrack design takes advantage of a narrow (Fig. S1) but sensitive (Fig. S2a) targeted NGS panel to detect a few major cancer drivers. Therefore, it was not expected to detect circulating alterations in most patients. Accordingly, 10/18 (54%) patients who were monitored until progression did not display alterations or quantitative changes in their levels (6 and 4 patients, respectively). However, and interestingly, all 3 patients who progressed exclusively due to cerebral metastases (Fig. S7) were included in this non-informative, LB-negative subset. This is not surprising since brain involvement is best monitored through the cerebrospinal fluid [19]. In the remaining 8 patients (44%) progression as per medical imaging was anticipated by 2.6 (range 0.7-4.6) months on average. Although shorter than in other settings, this anticipation may be clinically useful since the expected median PFS during T-DM1 treatment is about 6.4 months (range 4.8-7.7 months) in real life studies [4].
LB identifies positive and negative PFS predictors

Most likely due to the limited case accrual, none of the mutated genes and variants seen in either tissue or blood at baseline significantly correlated with PFS (not shown). We then hypothesized that dynamic, LB-informed criteria might better identify variants associated with different outcomes. Then, the VAFs of tumor variants were graphed (baseline vs progression) as in Fig. 1d. Three distinct trends were evident: some variants (e.g. PIK3CA p.H1047R) consistently increased in all the patients in whom they were observed, others (e.g. HER2 mutations) consistently decreased, and others yet (e.g. TP53) were inconsistent, e.g. they displayed increases in some patients and decreases in others. Alterations were then sorted by trend, color-coded (red for consistent increases, green for consistent decreases, and blue for inconsistent changes), and ranked for the number of patients in whom they had been observed. Additional ranking for magnitude of the observed change resulted in the pseudocolor distribution shown in Fig. 1e. Consistent trends were accepted, whereas inconsistent observations/alterations were rejected because uninformative with respect to clonal outcome. Patients with at least one red alteration, even in presence of green co-mutations, were assumed to carry a dominant negative predictor, whereas exclusive presence of a green alteration was hypothesized to be a positive predictor. Although larger numbers are needed to draw firm conclusions, this dynamic classification identified two groups of patients with significantly (p < 0.05) different PFS (Fig. 1f). Interestingly, most PFS values of patients bearing negative predictors clustered far below the median, suggesting that negative predictors are particularly robust and possibly coincide with drivers of clinical resistance to T-DM1. Positive and negative predictors were confirmed by preliminary analysis including 12 additional patients from a larger ongoing multicenter study (not shown).

Circulating predictors are actionable

Interrogation of the OncoKB knowledge base [20] revealed that 20/24 (83%) blood variants in 13/18 (72%) of the patients progressing on T-DM1 were actionable, mostly at level 3A, e.g. in indication for non-HER2 advanced BC (Table S1). This suggests bypass of the HER2 blockade through forced, and systematic, molecular subtype switch. Some alterations were actionable (e.g. HER2 mutations and lapatinib), but treatment was not considered because drugs had already been used in previous therapy cycles, e.g. these patients were assumed to carry refractory clonal (re-)expansions. Three patients with ESR1 and PI3KCA mutations were prioritized, and either referred to our intramural Molecular Tumor Board, or enrolled in clinical trials for off-label treatment with Fulvestrant, Everolimus plus Exemestane, and SYD987, under a strict LB monitoring scheme. All patients achieved PR lasting 7.2 to 8.6 months, and CT scans were mirrored by blood clearance of the target alteration selected during T-DM1 treatment (Fig. 1g). Thus, at least in these cases, LB identified circulating drivers, and not passengers, of T-DM1 escape. It remains to be determined whether and which alterations listed in Table S1, if any, are actionable in the post-T-DM1 setting.

Conclusions

In summary, LB identifies drivers/predictors (at extracranial sites only) of T-DM1 escape as they gradually replace HER2, suggesting systematic molecular subtype switch. Predictors of progression may be cryptic (blood-only), and include actionable ESR1 and PIK3CA mutations as well as MYC and FGFR1 amplifications. In contrast, other PIK3CA mutations and all tested HER2 mutations are wiped off by T-DM1 in weeks and may be associated with a more durable T-DM1 response.

Abbreviations

ctTNA: Circulating total tumor nucleic acids; dPCR: Digital PCR; HER2 BC: Breast carcinomas of the HER2-positive subtype; LB: Liquid biopsy; NGS: Next generation sequencing; PBMCs: Peripheral blood mononuclear cells; PD: Progressive disease; PFS: Progression-free survival; PR: Partial response; SD: Stable disease; SoC: Standard of care; T-DM1: Trastuzumab-emtansine.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12943-021-01438-z.

Additional file 1: Fig. S1. LiqBreasTrack study design. Retrospective (left) and prospective (middle-right) testing of archival tumor tissues and serial blood drawings. Targeted NGS was carried out before the first T-DM1 administration, on the occasion of revaluation by medical imaging, and at progression (*). dPCR with mutation-specific assays was performed on all blood drawings. Re-biopsy was occasionally assessed for confirmatory purposes. FFPE: formalin-fixed-paraffin embedded.

Additional file 2: Fig. S2. Testing accuracy and correlation statistics. (a) Limit of detection of blood NGS analysis performed in each patient. Values are automatically calculated by the Ion Reporter software v 5.16 as median LOD of all generated amplicons. (b) NGS sequencing depth on archival tissue (left and middle panels) and blood samples (right). Median values are indicated by the dotted line. (c-d) HER2 copy numbers estimated by NGS and dPCR in each plasma sample, and linear regression. (e-f) Linear regression of the abundance (VAF, variant allele frequency) of tumor alterations estimated by NGS and dPCR in tumor tissues and blood, as indicated. Frequency, confidence intervals (grey areas around best fit curve), p values and goodness of fit (R) are shown. LOD: limit of detection.

Additional file 3: Fig. S3. HER2 amplification in tumor tissue re-biopsies at progression. HER2 amplification was assessed in the last tumor tissue available before T-DM1 administration vs a tumor re-biopsy collected at disease progression from the same patients (n = 4). The cut-off value for HER2 amplification (blue line) is shown.

Additional file 4: Fig. S4. Clonal hematopoiesis. (a) dPCR testing of DNAs from tumor tissues and PBMCs from the two patients (out of 22) in whom clonal hematopoiesis (3 circulating TP53 mutations) was detected.
(b) ‘Zigzagging’ trajectories (no progressive trend for either increase or decrease discernible) of the same alterations in serial blood drawings. Red, blue and green dots: wild-type allele, mutated allele, and double-positive dPCR spots, respectively. NTC: no template control. PBMCs: peripheral blood mononuclear cells. VAF: variant allele frequency.

Additional file 5: Fig. S5. Genomic and clinical-biological profiling of tumor tissues and blood. Somatic mutations in (a) tumor tissues and (b) blood samples were arranged by patient number. Top graph: numbers of somatic mutations per patient. Top four rows: best response to T-DM1, and biological characterization of each tumor. All other rows: oncoprint of genomic alterations. Right side of oncoprint: numbers of mutations per gene. (c) Venn diagram: tumor mutational hits in tissue, blood and their intersection. SNVs: single nucleotide polymorphisms.

Additional file 6: Fig. S6. ctDNA trajectories during T-DM1 treatment. Representative results of LB with mutation-specific dPCR assays (lines) and ultra-deep NGS (selected time points; bars) in serial blood drawings. Trajectories are consistent with primary (a) and acquired (b) resistance, or response (c) to T-DM1. Shaded areas highlight outcome anticipation by LB (lead time), e.g. the time elapsed from progression (or response) assessed by LB, to progression (or response) assessed by clinical imaging. VAF: variant allele frequency.

Additional file 7: Fig. S7. Mutations from brain metastases are undetectable in blood. ETV6 and GATA3 mutations were assessed by dPCR in a brain metastasis surgically removed from pt. #5, and in blood obtained right before surgery. Red, blue and green dots identify WT, mutated and double dPCR positives. Copies per ml of the wild-type allele in plasma are noted: VAF: variant allele frequency.

Additional file 8: Table S1. Actionable level of circulating ctTNAs. * OncoKB highest level of evidence in advanced breast cancer.

Additional file 9.

Acknowledgements
The authors thank Dr. Emanuela Taraborelli, Elisabetta Bozzi, and Adele Petrica for assistance in blood drawing, data management and secretarial support.

Authors’ contributions
MA designed and performed NGS and dPCR assays, analysed the data, and wrote the paper. AF designed and coordinated all aspects of the clinical study, and wrote the paper. EG, CE, PR and EP collected and processed tissue and blood samples. CN, SG and VB provided clinical expertise, enrolled patients, and wrote the paper. GC coordinated MTB activities and critically evaluated molecular data. FC chaired and supervised the clinical study, and authored the manuscript. AF designed and performed NGS and dPCR assays, analysed the data, and critically evaluated molecular data. FC chaired and supervised the clinical study, and wrote the paper. All authors read and approved the final manuscript.

Funding
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC, Nuvenia Fellowship id. 19503 to MA), H2020 EU project ULTRAPLACAD (Grant Agreement n. 633937), Laziolnova ERBB2-2D project (Grant n. AO375-2020-36630) and IRCCS Regina Elena Scientific Direction intramural funding.

Availability of data and materials
Data supporting the conclusions of this article are available on the IRCCS Regina Elena National Cancer Institute website (www.flo.it) upon request.

Declarations
Ethics approval and consent to participate
This study was approved by the IRCCS Regina Elena National Cancer Institute Ethical Review Board (authorization ID #RS-857/16).

Consent for publication
Not applicable.

Competing interests
The authors declare no potential conflicts of interest with the present work.

Author details
1 Oncogenomics and Epigenetics, IRCCS Regina Elena National Cancer Institute, Via Elio Chianese, 53, 00144 Rome, Italy. 2 Medical Oncology I, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 3 Present Address: Precision Medicine Breast Cancer Unit, Scientific Directorate, Health of Woman and Child Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 4 Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 5 Specialization School in Oncology, Sapienza University of Rome, Rome, Italy. 6 Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 7 Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 8 Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy. 9 Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Received: 30 April 2021 Accepted: 26 September 2021
Published online: 29 November 2021

References
1. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–72.
2. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84.
3. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:17–28.
4. Conte B, Fabi A, Poggi F, Blondeaux E, Dellepiane C, D’Alonzo A, et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Cln Breast Cancer. 2020;20:e181–7.
5. Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, et al. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? Future Oncol. 2017;13:2791–7.
6. Li G, Guo J, Shen Q, Yadav DB, Silivkovski MX, Crocker LM, et al. Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther. 2018;17:1441–53.
7. Blanchette PS, Desautels DN, Pond GR, Bartlett JMS, Nofech-Mozes S, Yaffe M, et al. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. Breast Cancer Res Treat. 2018;170:169–77.
8. Ren Z, Li Y, Shen T, Hameed O, Siegel GP, Wei S. Prognostic factors in advanced breast cancer: race and receptor status are significant after development of metastasis. Pathol Res Pract. 2016;212:24–30.
9. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012–9.
10. Mittendorf EA, Wu Y, Scalltri M, Meric-Bernstam F, Hunt KK, Davood S, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009;15:7381–8.
11. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13:e78–85.
12. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48.
13. Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangratheep C, et al. Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011;104:1342–8.
14. Geversleben H, Garcia-Munilis I, Graesser MK, Schiavon G, Oisin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res. 2013;19:3276–84.
15. Ruifeng ZPY, Lihua Z, Shuangye S, Zhaoliang L, Yan W. Using digital PCR to detect HER2 amplification in breast and gastric cancer patients. Front Lab Med. 2018;2:102–8.

16. Modi S, Tsurutani J, Tamura K, Park H, Sagara Y, Murthy R, et al. Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study. Cancer Res. 2019;79:P6-17-02-P16-17-02.

17. Li J, Xiao Q, Yao L, Wang W, Goh J, Wang P, et al. HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment. Cell Cycle. 2019;18:1513–22.

18. Chen L, Yang L, Yao L, Kuang XY, Zuo WJ, Li S, et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun. 2018;9:1357.

19. De Mattos-Arruda L. Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid. ESMO Open. 2017;2:e000270.

20. Chakravarty D, Gao J, Phillips SM, Kundla R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;20:1–16.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.